Bachem Holding AG: directors' dealings · Switzerland · SIX SER

About Bachem Holding AG

Bachem Holding AG is a Swiss specialty chemicals and CDMO group focused on the development and manufacturing of peptides and oligonucleotides, two highly complex molecule classes that are increasingly important in next-generation therapeutics. The company is listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland under the ticker BANB, and it serves a global client base of pharmaceutical and biotechnology companies that outsource critical parts of the value chain, from early-stage development through to reliable commercial supply. Bachem was founded in 1971 by Peter Grogg in Liestal and later relocated to Bubendorf, where its headquarters and largest GMP manufacturing hub are now located. From its origins as a peptide synthesis laboratory, the company has grown into a global reference in TIDES manufacturing, with industrial and commercial operations across Europe, the United States and Asia. Its business model rests on two core pillars: clinical development and commercial production. Bachem supports customers across the full product lifecycle, including process development, analytical support, scale-up, quality control and GMP manufacturing. Its key offerings include peptide active pharmaceutical ingredients, therapeutic oligonucleotides and related intermediates, with exposure to innovative medicines in areas such as oncology, metabolic disease, rare diseases and targeted therapies. From a competitive standpoint, Bachem holds a strong position thanks to its scientific depth, long-standing peptide expertise and specialized industrial footprint. The group is widely regarded as one of the global leaders in its niche, supported by a reputation for technical reliability and long-term partnerships with major pharmaceutical customers. Its strategic priority is to expand manufacturing capacity in order to capture rising global demand for complex molecule therapeutics. Recent developments reinforce this growth narrative. In 2025, Bachem continued its capacity expansion program, notably at Bubendorf through Building K, and in the United States at Vista, California, where it acquired adjacent land for future expansion. The company also announced a long-term cooperation agreement for peptide development and supply. In its 2025 financial year results published in March 2026, Bachem reported sales growth and continued high EBITDA profitability, while proposing a higher dividend, underscoring a combination of growth, operational discipline and cash generation. For international investors, Bachem offers structurally attractive exposure to innovative healthcare, backed by a high-quality Swiss industrial base and a truly global operating platform.